×
About 838 results

ALLMedicine™ Adult T-cell Leukemia/lymphoma Center

Research & Reviews  320 results

Oral HDAC Inhibitor Tucidinostat (HBI-8000) in Patients with Relapsed or Refractory Adu...
https://doi.org/10.1111/cas.15431
Cancer Science; Utsunomiya A, Izutsu K et. al.

May 18th, 2022 - This multicenter, prospective Phase IIb trial evaluating the efficacy and safety of tucidinostat (HBI-8000) in patients with relapsed or refractory (R/R) adult T-cell leukemia/lymphoma (ATLL) was conducted in Japan. Eligible patients had R/R ATLL ...

Spindle cell tumor with histiocytic and myogenic marker expression in the lymph node of...
https://doi.org/10.1016/j.prp.2022.153935
Pathology, Research and Practice; Kubo T, Hirayama Y et. al.

May 8th, 2022 - Carriers of oncogenic human T-cell leukemia virus type 1 (HTLV-1) can develop adult T-cell leukemia/lymphoma (ATLL). While an increasing number of animal models of HTLV-1 infection have revealed that malignant tumors with a histiocytic phenotype c...

Identification and characterization of a novel enhancer in the HTLV-1 proviral genome.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065021
Nature Communications; Matsuo M, Ueno T et. al.

May 4th, 2022 - Human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus that causes adult T-cell leukemia/lymphoma (ATL), a cancer of infected CD4+ T-cells. There is both sense and antisense transcription from the integrated provirus. Sense transcription tend...

Dimethyl Fumarate Induces Apoptosis via Inhibiting NF-κB and STAT3 Signaling in Adult T...
https://doi.org/10.21873/anticanres.15709
Anticancer Research; Maeta T, Sato T et. al.

May 1st, 2022 - Adult T-cell leukemia (ATL) is a peripheral T lymphocytic malignancy caused by human T-cell leukemia virus type 1 (HTLV-1) infection. Despite treatment that includes novel agents that have been developed, most of ATL patients relapse and acquire m...

Exploration of mRNAs and miRNA classifiers for various ATLL cancer subtypes using machi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026691
BMC Cancer; Ghobadi MZ, Emamzadeh R et. al.

Apr 23rd, 2022 - Adult T-cell Leukemia/Lymphoma (ATLL) is a cancer disease that is developed due to the infection by human T-cell leukemia virus type 1. It can be classified into four main subtypes including, acute, chronic, smoldering, and lymphoma. Despite the c...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  6 results

Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT00924170

Feb 8th, 2022 - BACKGROUND: Cluster of differentiation 25 (CD25) (p55, Tac or interleukin receptor 2 (IL2Ra) is strongly expressed in virtually 100 % of patients with adult T-cell leukemia/lymphoma (ATL), a highly aggressive human T-lymphotropic virus type 1 (HTL...

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04102150

Jan 12th, 2022 - This Phase 2 study will be conducted to assess the efficacy and safety of valemetostat tosylate (DS-3201b) in participants with relapsed or refractory adult T-cell leukemia/lymphoma (r/r ATL).

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04848064

Oct 8th, 2021 - PRIMARY OBJECTIVE: I. To determine safety, tolerability, and determine the maximum tolerated dose (MTD) of IL-21 expanded, off the shelf, third-party natural killer (NK) cells and mogamulizumab in patients with relapsed/refractory cutaneous T-cell...

Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01336920

Jul 27th, 2018 - PRIMARY OBJECTIVES: I. To establish the maximum tolerated dose (MTD) of single agent carfilzomib in patients with relapsed and refractory peripheral T-cell lymphoma (PTCL) including angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell ...

Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1
https://clinicaltrials.gov/ct2/show/NCT00339638

Jul 2nd, 2017 - To characterize molecular markers for risk of adult T-cell leukemia/lymphoma (ATL), whose incidence rate differs greatly across geographic areas, we propose to examine the prevalence and level of viral and host immune response markers as well as t...

see more →

News  8 results

An International Experience at Home
https://www.onclive.com/view/an-international-experience-at-home

Dec 5th, 2020 - Christopher Dittus, DO, MPH I often find myself in awe of physicians who travel around the world seeking out the 2 most desirable aspects of medicine—patients in desperate need of medical care and patients with genuinely novel pathology. The dow...

NCCN Guidelines Reflect Recent FDA Approvals for Hematologic Malignancies
https://www.onclive.com/view/nccn-guidelines-reflect-recent-fda-approvals-for-hematologic-malignancies

Dec 5th, 2020 - Meletios A. Dimopoulos, MD New options for patients with hematologic malignancies stemming from recent FDA approvals are making an impact on treatment strategies recommended in the National Comprehensive Cancer Network (NCCN) Clinical Practice Gu...

Targeted Agents Lead Treatment Advances in T-Cell Lymphoma
https://www.onclive.com/view/targeted-agents-lead-treatment-advances-in-t-cell-lymphoma

Dec 4th, 2020 - Jasmine M. Zain, MD Results from the phase III ECHELON-2 trial set a precedent for targeted therapy in T-cell lymphoma by showing the benefit of adding brentuximab vedotin (Adcetris) to standard chemotherapy in patients with advanced CD30-express...

Systemic Epstein-Barr Virus–Positive T-cell Lymphoma of Childhood
https://www.mdedge.com/dermatology/article/211566/pediatrics/systemic-epstein-barr-virus-positive-t-cell-lymphoma-childhood/page/0/2?channel=45

Nov 5th, 2019 - Comment Prevalence and Presentation Epstein-Barr virus is a ubiquitous γ-herpesvirus with tropism for B cells, affecting more than 90% of the adult population worldwide. In addition to infecting B cells, EBV is capable of infecting T and NK cells,.

Cobomarsen shows early promise for treating ATLL
https://www.mdedge.com/hematology-oncology/article/194089/lymphoma-plasma-cell-disorders/cobomarsen-shows-early-promise
Jennifer Smith

Feb 7th, 2019 - LA JOLLA, CALIF. – Phase 1 results suggest cobomarsen is well tolerated and can maintain or improve responses in patients with previously treated adult T-cell leukemia/lymphoma (ATLL).

see more →